XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Data
 6 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Data Segment Data
The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.
Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.
Three Months Ended March 31,
(Millions of dollars)20252024
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$687 $430 $1,117 $662 $445 $1,107 
Medication Management Solutions662 149 811 609 162 772 
Pharmaceutical Systems149 426 575 157 413 570 
Advanced Patient Monitoring155 102 257 — — — 
Total segment revenues$1,653 $1,107 $2,760 $1,429 $1,020 $2,449 
Life Sciences
Specimen Management (a)$242 $213 $456 $236 $222 $458 
Diagnostic Solutions (a)189 250 440 201 267 468 
Biosciences142 209 352 142 235 377 
Total segment revenues$574 $673 $1,247 $579 $724 $1,304 
Interventional
Surgery$289 $94 $383 $287 $92 $379 
Peripheral Intervention269 212 481 264 225 489 
Urology and Critical Care323 77 400 347 78 424 
Total segment revenues$880 $384 $1,264 $898 $395 $1,292 
Total Company revenues$3,108 $2,164 $5,272 $2,906 $2,139 $5,045 
(a)    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.
Six Months Ended March 31,
(Millions of dollars)20252024
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$1,381 $860 $2,241 $1,301 $857 $2,159 
Medication Management Solutions1,321 291 1,612 1,203 315 1,518 
Pharmaceutical Systems253 740 993 285 717 1,002 
Advanced Patient Monitoring314 215 528 — — — 
Total segment revenues$3,268 $2,107 $5,375 $2,789 $1,890 $4,679 
Life Sciences
Specimen Management (a)$481 $437 $917 $469 $436 $905 
Diagnostic Solutions (a)402 512 914 411 524 935 
Biosciences295 418 713 285 466 752 
Total segment revenues$1,178 $1,367 $2,545 $1,166 $1,426 $2,592 
Interventional
Surgery$591 $187 $778 $568 $181 $748 
Peripheral Intervention522 432 954 498 444 943 
Urology and Critical Care629 160 789 634 156 789 
Total segment revenues$1,742 $779 $2,521 $1,699 $781 $2,480 
Total Company revenues $6,187 $4,253 $10,440 $5,655 $4,096 $9,751 
(a)    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.
Segment income for the three and six-month periods was as follows:
 Three Months Ended
March 31,		Six Months Ended
March 31,
(Millions of dollars)2025202420252024
Income Before Income Taxes
Medical (a)$550 $662 $1,043 $1,197 
Life Sciences377 415 760 787 
Interventional392 388 779 679 
Total Segment Operating Income1,319 1,465 2,582 2,663 
Integration, restructuring and transaction expense(90)(101)(182)(176)
Net interest expense (146)(99)(278)(176)
Other unallocated items (b)(720)(632)(1,453)(1,320)
Total Income Before Income Taxes$363 $633 $669 $991 
(a)The amounts for the three and six months ended March 31, 2025 included charges recorded to Cost of products sold of $76 million and $98 million, respectively, to adjust estimated future product remediation costs, and charges of $162 million and $342 million, respectively, due to a fair value step-up adjustment relating to Advanced Patient Monitoring's inventory on the acquisition date.
(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.